A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma.
To clarify the role of thermoradiotherapy for FIGO Stage IIIB cervical carcinomas, both the clinical response and survival of patients treated with radio- or thermoradiotherapy were investigated. Forty patients with Stage IIIB uterine cervix carcinoma were treated with external beam irradiation to the pelvis, combined with iridium 192 high-dose-rate intracavitary brachytherapy. All patients were divided randomly into the following two groups: the radiotherapy (RT) group of 20 patients, who underwent radiotherapy alone; and the thermoradiotherapy (TRT) group of 20 patients, who underwent three sessions of hyperthermia in addition to radiotherapy. The primary endpoint of this study was local complete response and survival. A complete response was achieved in 50% (10 of 20) in the RT group versus 80% (16 of 20) in the TRT group (p = 0.048). The 3-year overall survival and disease-free survival of the patients who were treated with TRT (58.2 and 63.6%) were better than those of the patients treated with RT (48.1 and 45%), but these differences were not significant. The 3-year local relapse-free survival of the patients who were treated with TRT (79.7%) was significantly better than that of the patients treated with RT (48.5%) (p = 0.048). TRT, as delivered in this trial, was well tolerated and did not significantly add to either the relevant clinical acute or long-term toxicity over radiation alone. TRT resulted in a better treatment response and 3-year local relapse-free survival rate than RT for patients with FIGO Stage IIIB cervical carcinoma.
Department of Radiology, Kansai Medical University, Moriguchi, Osaka, Japan. harima@takii.kmu.ac.jp
Y
Y
Harima
K
K
Nagata
K
K
Harima
V V
VV
Ostapenko
Y
Y
Tanaka
S
S
Sawada
D000368:Aged; D001918:Brachytherapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D011846:Radio Waves / Q000009:adverse effects; D000078702:Radiofrequency Therapy; D011882:Radiotherapy, High-Energy; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy*
D007496:Iridium Radioisotopes